VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX
Delisted
VIRX was delisted on the 3rd of February, 2025.
40 hedge funds and large institutions have $29.1M invested in Viracta Therapeutics, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
89% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 18
Holders
40
Holding in Top 10
–
Calls
$1.41M
Puts
$681K
Top Buyers
| 1 | +$238K | |
| 2 | +$215K | |
| 3 | +$189K | |
| 4 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$78.9K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$70K |
Top Sellers
| 1 | -$1.31M | |
| 2 | -$314K | |
| 3 | -$314K | |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$232K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$145K |